Seminars in liver disease最新文献_第6页

A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD. 新型生物标记物在 MASLD 中的应用：基于精准医学的方法。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-07-11 DOI: 10.1055/a-2364-2928

Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab

{"title":"A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD.","authors":"Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab","doi":"10.1055/a-2364-2928","DOIUrl":"10.1055/a-2364-2928","url":null,"abstract":"The new nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasizes a positive diagnosis based on cardiometabolic risk factors. This definition is not only less stigmatizing but also allows for subclassification and stratification, thereby addressing the heterogeneity of what was historically referred to as nonalcoholic fatty liver disease. The heterogeneity within this spectrum is influenced by several factors which include but are not limited to demographic/dietary factors, the amount of alcohol use and drinking patterns, metabolic status, gut microbiome, genetic predisposition together with epigenetic factors. The net effect of this dynamic and intricate system-level interaction is reflected in the phenotypic presentation of MASLD. Therefore, the application of precision medicine in this scenario aims at complex phenotyping with consequent individual risk prediction, development of individualized preventive strategies, and improvements in the clinical trial designs. In this review, we aim to highlight the importance of precision medicine approaches in MASLD, including the use of novel biomarkers of disease, and its subsequent utilization in future study designs.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"273-286"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gallstones: Prevention, Diagnosis, and Treatment. 胆结石：预防、诊断和治疗。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-08-02 DOI: 10.1055/a-2378-9025

Frank Lammert, Henning Wittenburg

{"title":"Gallstones: Prevention, Diagnosis, and Treatment.","authors":"Frank Lammert, Henning Wittenburg","doi":"10.1055/a-2378-9025","DOIUrl":"10.1055/a-2378-9025","url":null,"abstract":"Gallstones are common and affect up to 20% of the general adult population and >20% of them will develop symptoms or complications of cholelithiasis. The high risk of gallbladder stone formation can be reduced by ursodeoxycholic acid in the case of significant weight reduction resulting from diet or bariatric surgery. Laparoscopic cholecystectomy is indicated for symptomatic gallstones, as the risk of recurrence or complications increases over the course of the disease. Biliary colic is treated with nonsteroidal anti-inflammatory drugs and spasmolytics; opioids can also be used in cases of severe acute pain. Acute cholecystitis represents a common complication of gallbladder stones and a cholecystectomy should be performed early electively, i.e., within 24 hours of admission to hospital. Symptomatic bile duct stones are primarily treated endoscopically. Immediate anti-infective therapy is mandatory in acute cholangitis. Although knowledge on the genetics and pathophysiology of gallstones has increased, current treatment algorithms remain predominantly invasive, based on interventional endoscopy and surgery. Future efforts should focus on novel strategies to prevent the development of gallstones.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"394-404"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Neutrophils in the Development of Steatotic Liver Disease. 中性粒细胞在脂肪肝发病过程中的作用

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI: 10.1055/s-0044-1789207

You-Jin Choi, Yeonsoo Kim, Seonghwan Hwang

引用次数: 0

Combined Organ Transplantation in Patients with Advanced Liver Disease. 晚期肝病患者的联合器官移植。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1055/s-0044-1788674

Ingrid Wei Zhang, Isabella Lurje, Georg Lurje, Christoph Knosalla, Felix Schoenrath, Frank Tacke, Cornelius Engelmann

{"title":"Combined Organ Transplantation in Patients with Advanced Liver Disease.","authors":"Ingrid Wei Zhang, Isabella Lurje, Georg Lurje, Christoph Knosalla, Felix Schoenrath, Frank Tacke, Cornelius Engelmann","doi":"10.1055/s-0044-1788674","DOIUrl":"10.1055/s-0044-1788674","url":null,"abstract":"Transplantation of the liver in combination with other organs is an increasingly performed procedure. Over the years, continuous improvement in survival could be realized through careful patient selection and refined organ preservation techniques, in spite of the challenges posed by aging recipients and donors, as well as the increased use of steatotic liver grafts. Herein, we revisit the epidemiology, allocation policies in different transplant zones, indications, and outcomes with regard to simultaneous organ transplants involving the liver, that is combined heart-liver, liver-lung, liver-kidney, and multivisceral transplantation. We address challenges surrounding combined organ transplantation such as equity, utility, and logistics of dual organ implantation, but also advantages that come along with combined transplantation, thereby focusing on molecular mechanisms underlying immunoprotection provided by the liver to the other allografts. In addition, the current standing and knowledge of machine perfusion in combined organ transplantation, mostly based on center experience, will be reviewed. Notwithstanding all the technical advances, shortage of organs, and the lack of universal eligibility criteria for certain multi-organ combinations are hurdles that need to be tackled in the future.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"369-382"},"PeriodicalIF":4.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statins in Chronic Liver Disease: Review of the Literature and Future Role. 他汀类药物在慢性肝病中的应用：文献综述与未来作用。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-03 DOI: 10.1055/a-2319-0694

Nguyen Pham, Jihane N Benhammou

引用次数: 0

Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment. 抗生素和抗真菌药的肝毒性及其在肝功能受损情况下的安全使用。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-13 DOI: 10.1055/s-0044-1787062

J Ma, E S Björnsson, N Chalasani

引用次数: 0

Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together? 克服肝癌患者对免疫检查点阻断剂的耐药性--强强联手？

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-28 DOI: 10.1055/a-2334-8311

Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich

{"title":"Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?","authors":"Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich","doi":"10.1055/a-2334-8311","DOIUrl":"10.1055/a-2334-8311","url":null,"abstract":"Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is one of the most common and deadliest tumors worldwide. While surgical resection or liver transplantation are the best option in early disease stages, these tumors often present in advanced stages and systemic treatment is required to improve survival time. The emergence of immune checkpoint inhibitor (ICI) therapy has had a positive impact especially on the treatment of advanced cancers, thereby establishing immunotherapy as part of first-line treatment in HCC and CCA. Nevertheless, low response rates reflect on the usually cold or immunosuppressed tumor microenvironment of primary liver cancer. In this review, we aim to summarize mechanisms of resistance leading to tumor immune escape with a special focus on the composition of tumor microenvironment in both HCC and CCA, also reflecting on recent important developments in ICI combination therapy. Furthermore, we discuss how combination of ICIs with established primary liver cancer treatments (e.g. multikinase inhibitors and chemotherapy) as well as more complex combinations with state-of-the-art therapeutic concepts may reshape the tumor microenvironment, leading to higher response rates and long-lasting antitumor immunity for primary liver cancer patients.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"159-179"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. 代谢相关肝细胞癌的分子谱系。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-03-18 DOI: 10.1055/a-2289-2298

Takahiro Kodama, Tetsuo Takehara

{"title":"Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.","authors":"Takahiro Kodama, Tetsuo Takehara","doi":"10.1055/a-2289-2298","DOIUrl":"10.1055/a-2289-2298","url":null,"abstract":"This review examines the latest epidemiological and molecular pathogenic findings of metabolic-associated hepatocellular carcinoma (HCC). Its increasing prevalence is a significant concern and reflects the growing burden of obesity and metabolic diseases, including metabolic dysfunction-associated steatotic liver disease, formerly known as nonalcoholic fatty liver disease, and type 2 diabetes. Metabolic-associated HCC has unique molecular abnormality and distinctive gene expression patterns implicating aberrations in bile acid, fatty acid metabolism, oxidative stress, and proinflammatory pathways. Furthermore, a notable frequency of single nucleotide polymorphisms in genes such as patatin-like phospholipase domain-containing 3, transmembrane 6 superfamily member 2, glucokinase regulator, and membrane-bound O-acyltransferase domain-containing 7 has been observed. The tumor immune microenvironment of metabolic-associated HCC is characterized by unique phenotypes of macrophages, neutrophils, and T lymphocytes. Additionally, the pathogenesis of metabolic-associated HCC is influenced by abnormal lipid metabolism, insulin resistance, and dysbiosis. In conclusion, deciphering the intricate interactions among metabolic processes, genetic predispositions, inflammatory responses, immune regulation, and microbial ecology is imperative for the development of novel therapeutic and preventative measures against metabolic-associated HCC.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"147-158"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives. 肝癌免疫微环境的异质性：新的单细胞和空间视角

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-24 DOI: 10.1055/s-0044-1787152

Caiyi Cherry Li, Meng Liu, Hsin-Pei Lee, Wenqi Wu, Lichun Ma

引用次数: 0

This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. 这就是 MASLD 的样子：多参数磁共振成像方案的潜力。

IF 4.3 3区医学

Seminars in liver disease Pub Date : 2024-05-01 Epub Date: 2024-05-28 DOI: 10.1055/a-2334-8525

Anja M Fischer, Nazim Lechea, Harvey O Coxson

{"title":"This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol.","authors":"Anja M Fischer, Nazim Lechea, Harvey O Coxson","doi":"10.1055/a-2334-8525","DOIUrl":"10.1055/a-2334-8525","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with a broad spectrum defined by liver biopsy. This gold standard method evaluates three features: steatosis, activity (ballooning and lobular inflammation), and fibrosis, attributing them to certain grades or stages using a semiquantitative scoring system. However, liver biopsy is subject to numerous restrictions, creating an unmet need for a reliable and reproducible method for MASLD assessment, grading, and staging. Noninvasive imaging modalities, such as magnetic resonance imaging (MRI), offer the potential to assess quantitative liver parameters. This review aims to provide an overview of the available MRI techniques for the three criteria evaluated individually by liver histology. Here, we discuss the possibility of combining multiple MRI parameters to replace liver biopsy with a holistic, multiparametric MRI protocol. In conclusion, the development and implementation of such an approach could significantly improve the diagnosis and management of MASLD, reducing the need for invasive procedures and paving the way for more personalized treatment strategies.","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"226-238"},"PeriodicalIF":4.3,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0